Mercurna closes Pre‑Seed financing and prepares for next growth phase

Mercurna is excited to announce the successful closing of its extended Pre‑Seed financing round, an important milestone that enables us to accelerate the development of our lead program, mCura1 and advance our proprietary kidney-targeted delivery platform.

9 April 2026

Mercurna closes extended Pre‑Seed financing, expanding on the 2023 raise and strengthening its position as a pioneer in targeted mRNA therapeutics as we prepare for our upcoming Seed round. 

The funding was supported by a committed group of informal investors and the regional investment agency OostNL, who bring a combination of strategic insights, entrepreneurial experience, and long‑term support to our next phase of growth. Their commitment underscores the strength of our scientific foundation and the rapidly expanding potential of targeted mRNA technologies.

“Closing this financing round marks an exciting inflection point for Mercurna,” said Jenny van Asbeck‑van der Wijst, CEO of Mercurna. “This funding enables us to accelerate the development of our lead candidate and continue building the capabilities needed to bring targeted mRNA therapies closer to the clinic. It also positions us strongly as we prepare for our upcoming financing round.”

With this Pre‑Seed funding, Mercurna is:

• Advancing mCura1 toward IND‑enabling activities, supported by strong preclinical proof‑of‑concept.
• Strengthening our ligand‑directed targeting technology, enabling precise delivery of RNA to disease‑driving tissues.
• Deepening strategic collaborations that enhance our nanomedicine, mRNA engineering, and targeted therapeutic development.

This milestone builds momentum for the company at a pivotal time, following recent achievements including new technological advancements, expanded partnerships, and growing international recognition.

Looking ahead, Mercurna is now gearing up for its Seed financing round to further accelerate the clinical translation of targeted mRNA therapeutics and expand the company’s innovative pipeline.